Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success

Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.

Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases

Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)